[Shanghai, China, May 28, 2026] SciGene Pharmaceuticals today announced the official launch of its novel antibiotic, telavancin hydrochloride for injection, in China for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of Staphylococcus aureus.

The commercial launch of telavin hydrochloride for injection in China provides a new treatment option that combines a unique dual bactericidal mechanism with clinical convenience for the treatment of infections caused by multidrug-resistant Gram-positive bacteria, especially severe pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA).

Long-lasting antibacterial activity to combat drug resistance challenges
Infections caused by Staphylococcus aureus are highly dangerous. With the widespread use of antibiotics, drug-resistant strains such as MRSA are constantly emerging, exhibiting resistance to multiple antibiotics and sensitivity only to a few drugs such as vancomycin. Furthermore, even within the same class of antibiotics, different subspecies may exhibit differences in antibacterial activity.

Tieravancin hydrochloride for injection is a rapidly killing lipoglycopeptide antibiotic with bactericidal activity against Gram-positive pathogens, including MRSA. Its unique dual bactericidal mechanism—inhibiting bacterial cell wall synthesis and binding to the bacterial cell membrane to interfere with membrane barrier function—is a mechanism of action not possessed by vancomycin, enabling it to exert its bactericidal effect rapidly while reducing the induction of drug resistance.

It is noteworthy that two published in vitro studies (covering more than 24,000 and 15,000 clinical isolates, respectively) showed that telavin hydrochloride for injection maintained its initial antimicrobial activity against refractory and multidrug-resistant bacteria more than a decade after its launch in the United States [1] [2] .
Only one dose per day is needed; studies show higher cure rates.
Compared with vancomycin, telavin has a longer half-life and only needs to be administered once a day [3] , which greatly improves patient compliance and ease of clinical application. In addition, the drug does not require therapeutic drug monitoring.

Data from the ATTAIN study showed that telavancin had a higher cure rate than vancomycin in a microbiologically evaluable (ME) population analysis of Staphylococcus aureus infection [4] .
Innovative options for clinical anti-infection
Saisheng Pharmaceuticals has the exclusive rights to develop and commercialize telavanin hydrochloride for injection in China and Vietnam.

Mr. Zhao Hong, President and CEO of SciSheng Pharmaceuticals, stated, “The successful launch of telavancin hydrochloride for injection in China marks another significant milestone for SciSheng Pharmaceuticals in the field of anti-infectives. Currently, MRSA remains a serious challenge and poses a significant clinical threat in respiratory infections, especially hospital-acquired infections. Telavancin hydrochloride for injection, with its unique dual bactericidal mechanism, broad antibacterial spectrum, and once-daily dosing regimen, improves efficacy while maintaining clinical convenience, providing an important new anti-infective option for critically ill patients in China. In the future, SciSheng Pharmaceuticals will continue to deepen its expertise in the fields of critically ill infections and oncology, focusing on unmet clinical needs, accelerating the launch of more innovative products in China, and contributing more to the ‘Healthy China 2030’ initiative.”
References
[1] Duncan LR, Mendes RE, Pfaller MA, et al. Antimicrobial activity of telavancin tested in vitro against a global collection of Gram-positive pathogens, including multidrug-resistant isolates (2015-2017). Microb Drug Resist. 2020;26(8):934-943.
[2] Duncan LR, Sader HS, Pfaller MA, et al. Regional analysis of telavancin and comparator antimicrobial activity against multidrug-resistant Staphylococcus aureus collected in the USA 2014-2016. J Glob Antimicrob Resist. 2020;20:118-123.
[3] VIBATIV [Package Insert]. Nashville, TN: Cumberland Pharmaceuticals Inc.; November 2023.
[4] Rubinstein E, et al. Telavancin versus vancomycin for hospital-acquired pneumonia due to Gram-positive pathogens. Clin Infect Dis. 2011; 52(1): 31-40.

https://mp.weixin.qq.com/s/n-KcmHs8qRLBtysR1AJ7Ug